Mabion Valuation
Is MAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MAB (PLN16.52) is trading above our estimate of fair value (PLN1.96)
Significantly Below Fair Value: MAB is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MAB?
Other financial metrics that can be useful for relative valuation.
What is MAB's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | zł267.00m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.7x |
Enterprise Value/EBITDA | 3.4x |
PEG Ratio | -0.06x |
Price to Earnings Ratio vs Peers
How does MAB's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 61.8x | ||
SVE Synthaverse | 71.7x | n/a | zł341.3m |
BIO BIOTON | 132.1x | n/a | zł300.5m |
GEN Genomed Spólka Akcyjna | 39.4x | n/a | zł39.1m |
SPRO Spero Therapeutics | 3.9x | -2.9% | US$86.8m |
MAB Mabion | 6.5x | -103.2% | zł267.0m |
Price-To-Earnings vs Peers: MAB is good value based on its Price-To-Earnings Ratio (6.5x) compared to the peer average (61.8x).
Price to Earnings Ratio vs Industry
How does MAB's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: MAB is good value based on its Price-To-Earnings Ratio (6.5x) compared to the European Biotechs industry average (31.5x).
Price to Earnings Ratio vs Fair Ratio
What is MAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 6.5x |
Fair PE Ratio | 3.1x |
Price-To-Earnings vs Fair Ratio: MAB is expensive based on its Price-To-Earnings Ratio (6.5x) compared to the estimated Fair Price-To-Earnings Ratio (3.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | zł16.52 | zł15.83 -4.2% | 14.2% | zł18.50 | zł13.00 | n/a | 3 |
Apr ’25 | zł16.30 | zł15.57 -4.5% | 7.3% | zł16.70 | zł14.00 | n/a | 3 |
Mar ’25 | zł16.99 | zł15.57 -8.4% | 7.3% | zł16.70 | zł14.00 | n/a | 3 |
Feb ’25 | zł18.13 | zł15.57 -14.1% | 7.3% | zł16.70 | zł14.00 | n/a | 3 |
Jan ’25 | zł18.15 | zł15.57 -14.2% | 7.3% | zł16.70 | zł14.00 | n/a | 3 |
Dec ’24 | zł21.48 | zł15.57 -27.5% | 7.3% | zł16.70 | zł14.00 | n/a | 3 |
Nov ’24 | zł17.00 | zł15.35 -9.7% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
Oct ’24 | zł16.99 | zł15.35 -9.7% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
Sep ’24 | zł16.79 | zł15.35 -8.6% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
Aug ’24 | zł18.00 | zł15.35 -14.7% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
Jul ’24 | zł16.44 | zł15.35 -6.6% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
Jun ’24 | zł17.00 | zł15.35 -9.7% | 8.8% | zł16.70 | zł14.00 | n/a | 2 |
May ’24 | zł18.45 | zł14.75 -20.1% | 5.1% | zł15.50 | zł14.00 | zł16.28 | 2 |
Apr ’24 | zł17.82 | zł15.75 -11.6% | 1.6% | zł16.00 | zł15.50 | zł16.30 | 2 |
Mar ’24 | zł20.69 | zł15.75 -23.9% | 1.6% | zł16.00 | zł15.50 | zł16.99 | 2 |
Feb ’24 | zł22.64 | zł15.75 -30.4% | 1.6% | zł16.00 | zł15.50 | zł18.13 | 2 |
Jan ’24 | zł21.00 | zł15.75 -25.0% | 1.6% | zł16.00 | zł15.50 | zł18.15 | 2 |
Dec ’23 | zł21.57 | zł16.25 -24.7% | 4.6% | zł17.00 | zł15.50 | zł21.48 | 2 |
Nov ’23 | zł20.70 | zł16.25 -21.5% | 4.6% | zł17.00 | zł15.50 | zł17.00 | 2 |
Oct ’23 | zł20.61 | zł26.00 +26.2% | 7.7% | zł28.00 | zł24.00 | zł16.99 | 2 |
Sep ’23 | zł23.00 | zł26.00 +13.0% | 7.7% | zł28.00 | zł24.00 | zł16.79 | 2 |
Aug ’23 | zł33.14 | zł26.00 -21.5% | 7.7% | zł28.00 | zł24.00 | zł18.00 | 2 |
Jul ’23 | zł24.50 | zł26.00 +6.1% | 7.7% | zł28.00 | zł24.00 | zł16.44 | 2 |
Jun ’23 | zł26.30 | zł61.50 +133.8% | 61.0% | zł99.00 | zł24.00 | zł17.00 | 2 |
May ’23 | zł28.24 | zł68.50 +142.6% | 44.5% | zł99.00 | zł38.00 | zł18.45 | 2 |
Analyst Forecast: Target price is lower than the current share price.